We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Applying a Closed, Modular, Semi-Automated System to CAR T Cell Therapy Manufacturing
Webinar

Applying a Closed, Modular, Semi-Automated System to CAR T Cell Therapy Manufacturing

Applying a Closed, Modular, Semi-Automated System to CAR T Cell Therapy Manufacturing
Webinar

Applying a Closed, Modular, Semi-Automated System to CAR T Cell Therapy Manufacturing

Dr Yongchang Ji
Dr Yongchang Ji
Manager of Product Applications Cell and Gene Therapy Thermo Fisher Scientific
 Dr Semsi Ensari
Dr Semsi Ensari
Senior Director Kite Pharma
Dr Nathan Moore
Dr Nathan Moore
Associate Director, Engineering & Automation Cell Therapies, Pharmaceutical Sciences Takeda

Cell-based chimeric antigen receptor (CAR) T cell therapies have rapidly advanced in recent years, with a variety of targets in clinical research and several FDA approved products already on the market. There has been tremendous effort to make CAR T cells more effective, safe and persistent when treating patients. On the manufacturing side, however, errors, lot-to-lot variation and contamination can be associated with open processes and manual handling of CAR T cells. 

Watch this webinar to learn about:

  • The various systems needed to develop and manufacture CAR T cell therapies
  • The benefits of implementing closed, GMP-compliant, digitally connected solutions at earlier stages in CAR T cell therapy development
  • The modular solutions that Thermo Fisher Scientific can provide to assist in the implementation of a CAR T cell therapy manufacturing process
Advertisement